Phase 3 N=42 Comparing Ways to Freeze the Nerve That Provides Thigh Sensation
Meralgia Paresthetica
Primary: Anesthesia Related Time — 554; 480 seconds — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Surgical Treatment of Post-surgical Mastectomy Pain Utilizing the Regenerative Peripheral Nerve Interface
Post-Mastectomy Chronic Pain Syndrome
Primary: Change in Pain Level — 6.9; 0.6; 4.4; 2.5 score on a scale
N/A N=34 Lidocaine for Diabetic Peripheral Neuropathy
Diabetes · Peripheral Neuropathy · Pain
Primary: Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS) — 33; 51 percentage of pain change from baseline — p=0.03
Phase 2 N=132 Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
N/A N=140 Effect of Exercise and Surgical Weight Loss on Polyneuropathy
Polyneuropathies · Obesity · Bariatric Surgery Candidate
Primary: Intraepidermal Nerve Fiber Density (IENFD) at the Proximal Thigh — 11.9; 12.7; 9.8; 11 fibers/mm — p=0.15
Phase 3 N=542 Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain
Neuropathic Pain
Primary: Baseline Mean Pain Score — 6.41; 6.54 units on a scale
N/A N=116 Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)
Shoulder Pain · Shoulder Impingement Syndrome · Shoulder Tendinitis
Primary: Change in - Short Form (SF) Question 3 (BPI-SF3) — 6.90; 7.05; 3.58; 3.96 units on a scale
N/A N=9 Treatment of Painful Digital Neuroma Using A Pedicled Nerve Flap
Painful Digital Neuroma
Primary: Static 2-point Discrimination Test — 7.3 mm
Phase 2 N=59 A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica
Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
Primary: Percent Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) Score at Week 4. — -44.37; -50.37 percentage of change from…
N/A N=16 Thermal-Imaging Comparison of Nerve Blocks for Bilateral Mastectomy
Anesthesia, Conduction
Primary: Skin Temperature Increase From Baseline — 1.9; 2.3 degrees C
N/A N=44 Reversing Diabetic Peripheral Neuropathy Through Exercise
Peripheral Neuropathy · Diabetes
Primary: Body Mass Index (BMI) — 30.7 kg/m^2
Phase 4 N=121 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Diabetic Peripheral Neuropathic Pain (DPN) · Postherpetic Neuralgia (PHN) · HIV-related Neuropathic Pain (HIV)
Primary: Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS) — -3.8 scores on scale — p=< 0.0001
N/A N=12 Metabolic Syndrome and Fall Risk
Metabolic Syndrome · Autonomic Neuropathy
Primary: Four Square Step Test (FSST) — 11.04; 14.29 seconds
Phase 2 N=45 Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration
Small Fiber Neuropathy
Primary: Denervation of Skin — 0.1; 0.1 percent change — p=0.33
Phase 3 N=256 Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
Neuropathic Pain
Primary: Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase — 2.84; 3.62 score on scale — p=0.0018
Phase 4 N=368 P4 (Pregabalin for Peripheral Posttraumatic Pain)
Neuralgia
Primary: Weekly Mean Pain Score at End of Treatment (Week 8) From Daily Pain Diary — 4.61; 5.23 score on a scale — p=0.010
N/A N=13 BlueWind Medical Reprieve System for the Treatment of PNP
Peripheral Neuropathy
Primary: The Incidence of System and/or Procedure Related Serious Adverse Events (SAEs). — 1 Participants
N/A N=21 Neuromuscular Electrical Stimulation (NMES) in Patients With Intermittent Claudication
Intermittent Claudication · Peripheral Vascular Disease
Primary: Change From Baseline in Initial Walking Distance — 64.3 metres
N/A N=22 Nociceptive Pain Fiber Response
Painful Peripheral Diabetic Neuropathy
Primary: Changes in Small Nerve Fiber Density by Assessment of a Skin Biopsy Comparing Baseline to Day 60 — .1; .1 nerve fibers / mm squared
N/A N=22 Characterization of Transient Alterations of Cutaneous Sensory Nerve Function by Cryolipolysis
Adiposity
Primary: Vibration Detection Threshold (VDT) — 26.3; 19 (um/sec)